Navigation Links
In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer

Following its Approval, Erbitux Will Earn Gold-Standard Status in 2011,

According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on overall survival is the attribute that most influences oncologists' prescribing decisions in the treatment of stage III colon cancer. Clinical data and expert opinion shows that Bristol-Myers Squibb/ImClone Systems/Merck KGaA's Erbitux and Roche/Genentech/Chugai's Avastin have advantages in this attribute when used in combination with sales-leading FOLFOX4 treatment. FOLFOX4 is comprised of oxaliplatin (Sanofi-Aventis's Eloxatin/Eloxatine, Yakult's Elplat), 5- fluorouracil and leucovorin.

The new report entitled Colon Cancer (Stage III): Therapies Must Increase Survival over FOLFOX to Reach Blockbuster Status finds that surveyed oncologists indicate that a therapy which improves disease-free survival over FOLFOX4 at three years would earn a 60% patient share and achieve blockbuster status. The report forecasts that Avastin, in combination with FOLFOX4, will earn a 22% patient share in the U.S. stage III colon cancer market in 2016. Additionally, owing to its efficacy, safety and tolerability, Erbitux in combination with FOLFOX4 will earn gold-standard status for stage III colon cancer in 2011, following its approval for the indication in 2010 in the U.S. and Europe.

"When using both drugs in combination with FOLFOX4, experts gave Erbitux a slightly higher score over Avastin in safety and tolerability," said Marcus Hoyle, analyst at Decision Resources. "Oncologists indicated that the cardiovascular toxicity associated with VEGF inhibitors, such as Avastin, has a more negative impact on their prescribing decisions than the tissue disorders associated with EGFR inhibitors, such as Erbitux."

About the Report

Colon Cancer (Stage III): Therapies Must Increase Survival over FOLFOX to Reach Blockbuster Status is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Combination of Thyroid Medicines Not Necessary
2. Combination therapy improves survival for certain prostate cancer patients
3. Enlarged Prostate Treatment Study Shows Combination of AVODART(R) and Tamsulosin Provides Greater Benefit Than Either Medication Alone
4. Drug combination shrinks breast cancer metastases in brain
5. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
6. 3-drug combination extremely promising as first-line therapy for multiple myeloma
7. Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
8. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
9. Drug combination effective against multiple myeloma, researchers show
10. HIV drug resistance risk in mothers reduced by combination of common drugs
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
(Date:12/1/2015)... ... ... ClinicoEconomics and Outcomes Research has published the ... ”. , As corresponding author Dr Ankita Modi says “Pre-existing gastrointestinal events may ... a large US managed care database, women aged 55 years or older with ...
(Date:12/1/2015)... ... December 01, 2015 , ... Physicians’ Education Resource®, ... (CME), today announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will ... detection and treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Growth in ... part due to decreases in utilization of hospital and nonhospital care, according to a ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the ... North America Annual Meeting from November 29 to December 4, 2015. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage ... (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced ... Radiological Society of North America (RSNA) 2015 annual meeting through December 3 in ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that it has reached its enrollment ... Phase 3 clinical trial of aldoxorubicin in patients with ... to be completed in Q1 2016. The Phase 3 trial ... Special Protocol Assessment from the FDA at 79 sites ...
Breaking Medicine Technology: